{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T12:51:13Z","timestamp":1764334273188,"version":"3.46.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T00:00:00Z","timestamp":1764288000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T00:00:00Z","timestamp":1764288000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Public Health"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Although the safety of the BBIBP-CorV (Sinopharm) vaccine has been confirmed in both adults and children, safety data remain limited for individuals under 18 years of age. This longitudinal study in Iran aimed to investigate reactogenicity, breakthrough infections, and serious adverse events following Sinopharm vaccination in this population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this cohort event monitoring study, children and adolescents aged 5 to 18 Years in the eight cities around the country were invited to participate after receiving the first dose of the vaccine. The assessment of local and systemic reactogenicities was conducted through daily telephone calls for up to seven days following the first and second doses of the vaccine. Severe adverse events, adverse events of special interest (AESI), and COVID-19 infections were monitored with weekly follow-ups. Follow-up lasted for 13 weeks for those who received one dose of the vaccine and 17 weeks for those who received two doses. Adverse events were reported as percentages along with 95% confidence intervals (CI). The total person-time at risk was used to calculate the incidence rate of COVID-19 infections, and factors associated with COVID-19 were analyzed using Cox survival analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among the 18,528 participants (50.5% female), the mean age was 11.9\u2009\u00b1\u20093.4 years (age range: 4.6\u201318.6). Only 57.4% of participants received the second dose of the vaccine. The incidence rate of COVID-19 infection was 28.9 (95% CI: 26.4\u201331.6) per 100,000 person-days. Two cases were classified as AESI: one case of generalized convulsion and one case of diabetic ketoacidosis. Reactogenicity was investigated in a subset of 945 participants, 184 of whom received the second vaccine dose. The most frequent local and systemic reactogenicity events on the first day after vaccination were as follows: pain at the injection site\u201426.7% (95% CI: 23.5\u201329.8) after the first dose and 53.3% (95% CI: 46.0\u201360.5) after the second dose; headache\u20146.0% (95% CI: 4.4\u20137.7) after the first dose and 8.7% (95% CI: 4.6\u201312.8) after the second dose; fatigue\u20143.7% (95% CI: 2.3\u20135.0) after the first dose and 7.1% (95% CI: 3.4\u201310.8) after the second dose; and malaise\u20142.9% (95% CI: 1.7\u20134.1) after the first dose and 7.6% (95% CI: 3.8\u201311.5) after the second dose. Most reactogenicity events subsided gradually and did not interfere with the participants\u2019 daily activities.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Sinopharm is a safe and well-tolerated vaccine option for children and adolescents and can be recommended for this population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12889-025-25308-1","type":"journal-article","created":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T12:49:38Z","timestamp":1764334178000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Safety of sinopharm COVID-19 vaccine in children and adolescents aged 5 to 18 years: a cohort event monitoring study"],"prefix":"10.1186","volume":"25","author":[{"given":"Mohammad Hassan","family":"Emamian","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sajad","family":"Sahab-Negah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sairan","family":"Nili","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Parvin","family":"Mangolian shahrbabaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alireza","family":"Ansari-moghaddam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad","family":"Fereidouni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mostafa","family":"Enayatrad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sepideh","family":"Mahdavi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roqayeh","family":"Aliyari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mansooreh","family":"Fateh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hamidreza","family":"Khajeha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zahra","family":"Emamian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elahe","family":"Behmanesh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hamid","family":"Sharifi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,28]]},"reference":[{"key":"25308_CR1","unstructured":"World Health Organization. COVID-19 epidemiological update \u2013 12 March 2025. 2025 [Available from: https:\/\/www.who.int\/publications\/m\/item\/covid-19-epidemiological-update-edition-177. Accessed 2025\/05\/22."},{"issue":"5152","key":"25308_CR2","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.15585\/mmwr.mm705152a3","volume":"70","author":"V Wanga","year":"2021","unstructured":"Wanga V, Gerdes ME, Shi DS, Choudhary R, Dulski TM, Hsu S, et al. Characteristics and clinical outcomes of children and adolescents Aged\u2009<\u200918 years hospitalized with COVID-19 - Six Hospitals, united States, July-August 2021. MMWR Morb Mortal Wkly Rep. 2021;70(5152):1766\u201372.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"12","key":"25308_CR3","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.31756","volume":"3","author":"ZJ Madewell","year":"2020","unstructured":"Madewell ZJ, Yang Y, Longini IM Jr., Halloran ME, Dean NE. Household transmission of SARS-CoV-2: a systematic review and meta-analysis. JAMA Netw Open. 2020;3(12):e2031756.","journal-title":"JAMA Netw Open"},{"issue":"1","key":"25308_CR4","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2023.2171185","volume":"19","author":"FP Bianchi","year":"2023","unstructured":"Bianchi FP, Stefanizzi P, Cuscianna E, Riformato G, Di Lorenzo A, Giordano P, et al. COVID-19 vaccination hesitancy among Italian parents: a systematic review and meta-analysis. Hum Vaccin Immunother. 2023;19(1):2171185.","journal-title":"Hum Vaccin Immunother"},{"key":"25308_CR5","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines11101556","author":"MS Iqbal","year":"2023","unstructured":"Iqbal MS, Khan SU, Qamer S, Vohra S. Vaccine hesitancy of COVID-19 among parents for their children in middle Eastern countries-a systematic review. Vaccines. 2023. https:\/\/doi.org\/10.3390\/vaccines11101556.","journal-title":"Vaccines"},{"key":"25308_CR6","unstructured":"World Health Organization. COVID-19 vaccine tracker and landscape 2023. 2023. [Available from: https:\/\/www.who.int\/publications\/m\/item\/draft-landscape-of-covid-19-candidate-vaccines. Accessed 2025\/05\/22."},{"key":"25308_CR7","unstructured":"World Health Organization. Interim statement on COVID-19 vaccination for children 2021 [updated 11 August 2022. 2022. Available from: https:\/\/www.who.int\/news\/item\/11-08-2022-interim-statement-on-covid-19-vaccination-for-children. Accessed 2025\/05\/22."},{"issue":"4","key":"25308_CR8","first-page":"17572","volume":"11","author":"S Mafinezhad","year":"2023","unstructured":"Mafinezhad S, Bayani G, Ehteshammanesh H, Langari M, Shokrollahi N, Bozorgnia Y, et al. Evaluation of the side effects of sinopharm and PastoCovac COVID-19 vaccines in children aged 5\u201312 years in Iran. J Pediatr Perspect. 2023;11(4):17572\u201382.","journal-title":"J Pediatr Perspect"},{"key":"25308_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2022.105196","volume":"153","author":"S Sadeghi","year":"2022","unstructured":"Sadeghi S, Kalantari Y, Shokri S, Fallahpour M, Nafissi N, Goodarzi A, et al. Immunologic response, efficacy, and safety of vaccines against COVID-19 infection in healthy and immunosuppressed children and adolescents aged 2\u201321 years old: a systematic review and meta-analysis. J Clin Virol. 2022;153:105196.","journal-title":"J Clin Virol"},{"issue":"5","key":"25308_CR10","doi-asserted-by":"publisher","first-page":"807","DOI":"10.3390\/vaccines10050807","volume":"10","author":"K Tawinprai","year":"2022","unstructured":"Tawinprai K, Siripongboonsitti T, Porntharukchareon T, Vanichsetakul P, Thonginnetra S, Niemsorn K, et al. Safety and immunogenicity of the BBIBP-CorV vaccine in adolescents aged 12 to 17 years in the Thai population: an immunobridging study. Vaccines. 2022. https:\/\/doi.org\/10.3390\/vaccines10050807.","journal-title":"Vaccines"},{"issue":"10","key":"25308_CR11","doi-asserted-by":"publisher","first-page":"4890","DOI":"10.1002\/jmv.27962","volume":"94","author":"N Tavakoli","year":"2022","unstructured":"Tavakoli N, Nafissi N, Shokri S, Fallahpour M, Soleimani S, Riahi T, et al. Pediatric and adolescent COVID-19 vaccination side effects: a retrospective cohort study of the Iranian teenage group in 2021. J Med Virol. 2022;94(10):4890\u2013900.","journal-title":"J Med Virol"},{"issue":"2","key":"25308_CR12","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/S1473-3099(21)00462-X","volume":"22","author":"S Xia","year":"2022","unstructured":"Xia S, Zhang Y, Wang Y, Wang H, Yang Y, Gao GF, et al. Safety and immunogenicity of an inactivated COVID-19 vaccine, BBIBP-CorV, in people younger than 18 years: a randomised, double-blind, controlled, phase 1\/2 trial. Lancet Infect Dis. 2022;22(2):196\u2013208.","journal-title":"Lancet Infect Dis"},{"issue":"10","key":"25308_CR13","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.3390\/vaccines10101765","volume":"10","author":"S Thonginnetra","year":"2022","unstructured":"Thonginnetra S, Tawinprai K, Niemsorn K, Promsena P, Tandhansakul M, Kasemlawan N, et al. Safety after BBIBP-CorV (Sinopharm) COVID-19 vaccine in adolescents aged 10\u201317 years in Thailand. Vaccines. 2022. https:\/\/doi.org\/10.3390\/vaccines10101765.","journal-title":"Vaccines"},{"issue":"3","key":"25308_CR14","doi-asserted-by":"publisher","first-page":"544","DOI":"10.3390\/vaccines11030544","volume":"11","author":"Z Koki\u0107","year":"2023","unstructured":"Koki\u0107 Z, Kon P, Djurkovi\u0107-Djakovi\u0107 O. Effectiveness of vaccination in preventing COVID-19: a community study comparing four vaccines. Vaccines. 2023. https:\/\/doi.org\/10.3390\/vaccines11030544.","journal-title":"Vaccines"},{"issue":"1","key":"25308_CR15","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-022-13575-1","volume":"22","author":"R Aliyari","year":"2022","unstructured":"Aliyari R, Mahdavi S, Enayatrad M, Sahab-Negah S, Nili S, Fereidooni M, et al. Study protocol: cohort event monitoring for safety signal detection after vaccination with COVID-19 vaccines in Iran. BMC Public Health. 2022;22(1):1153.","journal-title":"BMC Public Health"},{"key":"25308_CR16","unstructured":"World Health Organization. Protocol template to be used as template for observational study protocols: cohort event monitoring (\u200eCEM)\u200e for safety signal detection after vaccination with COVID-19 vaccines 2021. 2021. [Available from: https:\/\/apps.who.int\/iris\/handle\/10665\/342193. Accessed 2025\/05\/22."},{"key":"25308_CR17","unstructured":"World Health Organization, Interim recommendations for use of the inactivated COVID-19 vaccine BIBP developed by China National Biotec Group (\u200eCNBG)\u200e, Sinopharm. 2021. Available at: https:\/\/www.who.int\/publications\/i\/item\/WHO-2019-nCoV-vaccines-SAGE-recommendation-BIBP"},{"issue":"2","key":"25308_CR18","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/S1473-3099(21)00462-X","volume":"22","author":"S Xia","year":"2022","unstructured":"Xia S, Zhang Y, Wang Y, Wang H, Yang Y, Gao GF, et al. Safety and immunogenicity of an inactivated COVID-19 vaccine, BBIBP-CorV, in people younger than 18 years: a randomised, double-blind, controlled, phase 1\/2 trial. Lancet Infect Dis. 2022;22(2):196\u2013208. https:\/\/doi.org\/10.1016\/S1473-3099(21)00462-X.","journal-title":"Lancet Infect Dis"},{"issue":"6","key":"25308_CR19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0218807","volume":"14","author":"U Manuwald","year":"2019","unstructured":"Manuwald U, Schoffer O, Hegewald J, Gro\u00dfe J, Kugler J, Kapellen TM, et al. Ketoacidosis at onset of type 1 diabetes in children up to 14 years of age and the changes over a period of 18 years in Saxony, Eastern-Germany: a population based register study. PLoS ONE. 2019;14(6):e0218807. https:\/\/doi.org\/10.1371\/journal.pone.0218807.","journal-title":"PLoS ONE"},{"issue":"1","key":"25308_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/s12902-023-01424-0","volume":"23","author":"AS Alsudais","year":"2023","unstructured":"Alsudais AS, Alkanani RS, Fathi AB, Almuntashiri SS, Jamjoom JN, Alzhrani MA, et al. Autoimmune diabetes mellitus after COVID-19 vaccination in adult population: a systematic review of case reports. BMC Endocr Disord. 2023;23(1):164. https:\/\/doi.org\/10.1186\/s12902-023-01424-0.","journal-title":"BMC Endocr Disord"},{"issue":"4","key":"25308_CR21","doi-asserted-by":"publisher","DOI":"10.5812\/ijem-135866","volume":"21","author":"FB Albedaiwi","year":"2023","unstructured":"Albedaiwi FB, Alshammari M, Algeffari M, Alfouzan A, Alfouzan Y, Siddiq H, et al. Diabetic ketoacidosis after COVID-19 vaccine in patients with type 1 diabetes mellitus. Int J Endocrinol Metab. 2023;21(4):e135866. https:\/\/doi.org\/10.5812\/ijem-135866.","journal-title":"Int J Endocrinol Metab"},{"issue":"5","key":"25308_CR22","doi-asserted-by":"publisher","first-page":"560","DOI":"10.4239\/wjd.v14.i5.560","volume":"14","author":"B Joob","year":"2023","unstructured":"Joob B, Wiwanitkit V. COVID-19 vaccination and diabetic ketoacidosis. World J Diabetes. 2023;14(5):560\u20134. https:\/\/doi.org\/10.4239\/wjd.v14.i5.560.","journal-title":"World J Diabetes"},{"issue":"1","key":"25308_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.dsx.2021.102371","volume":"16","author":"V Ganakumar","year":"2022","unstructured":"Ganakumar V, Jethwani P, Roy A, Shukla R, Mittal M, Garg MK. Diabetic ketoacidosis (DKA) in type 1 diabetes mellitus (T1DM) temporally related to COVID-19 vaccination. Diabetes Metab Syndr. 2022;16(1):102371. https:\/\/doi.org\/10.1016\/j.dsx.2021.102371.","journal-title":"Diabetes Metab Syndr"},{"key":"25308_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2023.110723","volume":"201","author":"C Liu","year":"2023","unstructured":"Liu C, Guo MN, Chai Z, Xin Z, Chen G, Zimmet PZ, et al. Association between Covid-19 vaccination and incidence of type 1 diabetes in China: evidence from 14.14 million registered residents between 2007 and 2021. Diabetes Res Clin Pract. 2023;201:110723. https:\/\/doi.org\/10.1016\/j.diabres.2023.110723.","journal-title":"Diabetes Res Clin Pract"},{"issue":"6","key":"25308_CR25","doi-asserted-by":"publisher","first-page":"892","DOI":"10.4239\/wjd.v14.i6.892","volume":"14","author":"YF He","year":"2023","unstructured":"He YF, Ouyang J, Hu XD, Wu N, Jiang ZG, Bian N, et al. Correlation between COVID-19 vaccination and diabetes mellitus: a systematic review. World J Diabetes. 2023;14(6):892\u2013918. https:\/\/doi.org\/10.4239\/wjd.v14.i6.892.","journal-title":"World J Diabetes"},{"issue":"10","key":"25308_CR26","doi-asserted-by":"publisher","first-page":"3010","DOI":"10.1111\/epi.18102","volume":"65","author":"A Rafati","year":"2024","unstructured":"Rafati A, Jameie M, Amanollahi M, Pasebani Y, Salimi N, Kazemi MHF, et al. Association of new onset seizure and COVID-19 vaccines and long-term follow-up: a systematic review and meta-analysis. Epilepsia. 2024;65(10):3010\u201327. https:\/\/doi.org\/10.1111\/epi.18102.","journal-title":"Epilepsia"},{"issue":"1","key":"25308_CR27","doi-asserted-by":"publisher","DOI":"10.1186\/s40001-025-03015-2","volume":"30","author":"R Aliyari","year":"2025","unstructured":"Aliyari R, Emamian MH, Mahdavi S, Enayatrad M, Sahab-Negah S, Nili S, et al. Adverse events of special interest after vaccination with COVID-19 vaccines: a cohort event monitoring study in Iran. Eur J Med Res. 2025;30(1):764. https:\/\/doi.org\/10.1186\/s40001-025-03015-2.","journal-title":"Eur J Med Res"},{"issue":"6","key":"25308_CR28","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/S2352-4642(23)00078-0","volume":"7","author":"V Piechotta","year":"2023","unstructured":"Piechotta V, Siemens W, Thielemann I, Toews M, Koch J, Vygen-Bonnet S, et al. Safety and effectiveness of vaccines against COVID-19 in children aged 5\u201311 years: a systematic review and meta-analysis. Lancet Child Adolesc Health. 2023;7(6):379\u201391.","journal-title":"Lancet Child Adolesc Health"},{"issue":"9","key":"25308_CR29","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1080\/14760584.2022.2098719","volume":"21","author":"N Sutton","year":"2022","unstructured":"Sutton N, San Francisco Ramos A, Beales E, Smith D, Ikram S, Galiza E, et al. Comparing reactogenicity of COVID-19 vaccines: a systematic review and meta-analysis. Expert Rev Vaccines. 2022;21(9):1301\u201318.","journal-title":"Expert Rev Vaccines"},{"issue":"1","key":"25308_CR30","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-023-08103-4","volume":"23","author":"M Enayatrad","year":"2023","unstructured":"Enayatrad M, Mahdavi S, Aliyari R, Sahab-Negah S, Nili S, Fereidouni M, et al. Reactogenicity within the first week after Sinopharm, Sputnik V, AZD1222, and COVIran Barekat vaccines: findings from the Iranian active vaccine surveillance system. BMC Infect Dis. 2023;23(1):150.","journal-title":"BMC Infect Dis"},{"issue":"10","key":"25308_CR31","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.3390\/vaccines10101767","volume":"10","author":"AT Makadzange","year":"2022","unstructured":"Makadzange AT, Gundidza P, Lau C, Beta N, Myburgh N, Elose N, et al. Vaccine adverse events following COVID-19 vaccination with inactivated vaccines in Zimbabwe. Vaccines. 2022. https:\/\/doi.org\/10.3390\/vaccines10101767.","journal-title":"Vaccines"},{"key":"25308_CR32","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.ijid.2021.08.013","volume":"111","author":"BQ Saeed","year":"2021","unstructured":"Saeed BQ, Al-Shahrabi R, Alhaj SS, Alkokhardi ZM, Adrees AO. Side effects and perceptions following sinopharm COVID-19 vaccination. Int J Infect Dis. 2021;111:219\u201326.","journal-title":"Int J Infect Dis"},{"issue":"12","key":"25308_CR33","doi-asserted-by":"publisher","first-page":"6588","DOI":"10.1002\/jmv.27214","volume":"93","author":"QA Al Khames Aga","year":"2021","unstructured":"Al Khames Aga QA, Alkhaffaf WH, Hatem TH, Nassir KF, Batineh Y, Dahham AT, et al. Safety of COVID-19 vaccines. J Med Virol. 2021;93(12):6588\u201394.","journal-title":"J Med Virol"},{"issue":"10","key":"25308_CR34","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1016\/j.vaccine.2022.01.062","volume":"40","author":"FTT Lai","year":"2022","unstructured":"Lai FTT, Leung MTY, Chan EWW, Huang L, Lau LKW, Peng K, et al. Self-reported reactogenicity of coronavac (Sinovac) compared with Comirnaty (Pfizer-BioNTech): a prospective cohort study with intensive monitoring. Vaccine. 2022;40(10):1390\u20136.","journal-title":"Vaccine"},{"issue":"21","key":"25308_CR35","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.1001\/jama.2021.5374","volume":"325","author":"J Chapin-Bardales","year":"2021","unstructured":"Chapin-Bardales J, Gee J, Myers T. Reactogenicity following receipt of mRNA-based COVID-19 vaccines. JAMA. 2021;325(21):2201\u20132.","journal-title":"JAMA"},{"issue":"7","key":"25308_CR36","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.3390\/vaccines10071111","volume":"10","author":"L Bonzano","year":"2022","unstructured":"Bonzano L, Djuric O, Mancuso P, Fares L, Brancaccio R, Ottone M, et al. Incidence and characteristics of adverse events after COVID-19 vaccination in a population-based programme. Vaccines. 2022. https:\/\/doi.org\/10.3390\/vaccines10071111.","journal-title":"Vaccines"},{"issue":"1","key":"25308_CR37","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.jiac.2021.09.009","volume":"28","author":"M Saita","year":"2022","unstructured":"Saita M, Yan Y, Ito K, Sasano H, Seyama K, Naito T. Reactogenicity following two doses of the BNT162b2 mRNA COVID-19 vaccine: real-world evidence from healthcare workers in Japan. J Infect Chemother. 2022;28(1):116\u20139.","journal-title":"J Infect Chemother"},{"issue":"7","key":"25308_CR38","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofac314","volume":"9","author":"AI Scher","year":"2022","unstructured":"Scher AI, Berjohn CM, Byrne C, Colombo RE, Colombo CJ, Edwards MS, et al. An analysis of SARS-CoV-2 vaccine reactogenicity: variation by type, dose, and history, severity, and recency of prior SARS-CoV-2 infection. Open Forum Infect Dis. 2022;9(7):ofac314.","journal-title":"Open Forum Infect Dis"},{"issue":"1","key":"25308_CR39","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1080\/14760584.2023.2208216","volume":"22","author":"G Tiozzo","year":"2023","unstructured":"Tiozzo G, Louwsma T, Konings SRA, Vondeling GT, Perez Gomez J, Postma MJ, et al. Evaluating the reactogenicity of COVID-19 vaccines from network-meta analyses. Expert Rev Vaccines. 2023;22(1):410\u20138.","journal-title":"Expert Rev Vaccines"},{"key":"25308_CR40","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2022.876336","volume":"10","author":"S Ganesan","year":"2022","unstructured":"Ganesan S, Al Ketbi LMB, Al Kaabi N, Al Mansoori M, Al Maskari NN, Al Shamsi MS, et al. Vaccine side effects following COVID-19 vaccination among the residents of the UAE-an observational study. Front Public Health. 2022;10:876336.","journal-title":"Front Public Health"},{"issue":"10","key":"25308_CR41","first-page":"e47670","volume":"15","author":"MA Abdulkader","year":"2023","unstructured":"Abdulkader MA, Sr., Merza MA. Immediate and Long-Term adverse events of COVID-19 vaccines: A One-Year Follow-Up study from the Kurdistan region of Iraq. Cureus. 2023;15(10):e47670.","journal-title":"Cureus"},{"issue":"8","key":"25308_CR42","doi-asserted-by":"publisher","first-page":"474","DOI":"10.2471\/BLT.22.288073","volume":"100","author":"A Hosseinzadeh","year":"2022","unstructured":"Hosseinzadeh A, Sahab-Negah S, Nili S, Aliyari R, Goli S, Fereidouni M, et al. COVID-19 cases, hospitalizations and deaths after vaccination: a cohort event monitoring study, Islamic Republic of Iran. Bull World Health Organ. 2022;100(8):474\u201383.","journal-title":"Bull World Health Organ"},{"issue":"13","key":"25308_CR43","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1016\/j.vaccine.2022.02.039","volume":"40","author":"F Ismail AlHosani","year":"2022","unstructured":"Ismail AlHosani F, Eduardo Stanciole A, Aden B, Timoshkin A, Najim O, Abbas Zaher W, et al. Impact of the sinopharm\u2019s BBIBP-CorV vaccine in preventing hospital admissions and death in infected vaccinees: results from a retrospective study in the emirate of Abu Dhabi, united Arab Emirates (UAE). Vaccine. 2022;40(13):2003\u201310.","journal-title":"Vaccine"},{"issue":"5","key":"25308_CR44","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/j.anai.2024.01.011","volume":"132","author":"C Chen","year":"2024","unstructured":"Chen C, Song X, Murdock DJ, Marcus A, Hussein M, Jalbert JJ, et al. Association between allergic conditions and COVID-19 susceptibility and outcomes. Ann Allergy Asthma Immunol. 2024;132(5):637\u2013e457.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"6","key":"25308_CR45","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1002\/ppul.26403","volume":"58","author":"ASM Sallih","year":"2023","unstructured":"Sallih ASM, Wee MW, Zaki RA, Hng SY, Eg KP, Nathan AM, et al. The outcome of COVID-19 in children with chronic lung disease: systematic review and meta-analyses. Pediatr Pulmonol. 2023;58(6):1784\u201397.","journal-title":"Pediatr Pulmonol"}],"container-title":["BMC Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-025-25308-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12889-025-25308-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-025-25308-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T12:49:42Z","timestamp":1764334182000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpublichealth.biomedcentral.com\/articles\/10.1186\/s12889-025-25308-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,28]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["25308"],"URL":"https:\/\/doi.org\/10.1186\/s12889-025-25308-1","relation":{},"ISSN":["1471-2458"],"issn-type":[{"value":"1471-2458","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,28]]},"assertion":[{"value":"26 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the ethics committee of Shahroud University of Medical Sciences, Shahroud, Iran with the reference number of IR.SHMU.REC.1400.012. Participation in this study was entirely voluntary, and after explaining the study objectives and methods, a written consent form was obtained from all participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial number"}}],"article-number":"4196"}}